Conference Track

Advances in HCV Treatment: 2006

Source: CCO Independent Conference Coverage of the 2006 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Week 4 Virologic Response Useful Tool in Determining Treatment Duration for Genotype 2/3 Patients Receiving Peginterferon Alfa-2a Plus Ribavirin
FibroScan Diagnoses Cirrhosis Better Than Clinical Symptoms or Biochemical Measures
Peginterferon Alfa-2a Plus High-Dose Weight-Based Ribavirin and Extended Therapy Duration Results in Higher Rates of SVR and Early Treatment Discontinuation in HIV/HCV-Coinfected Patients
Genotype 1 Patients With Above-Average Body Weight and High Baseline HCV RNA May Benefit From Increased Peginterferon Alfa-2a and Ribavirin Dosing
24-Week Extension of Peginterferon Alfa-2b Plus Weight-Based Ribavirin Significantly Improved SVR Rates in HCV Genotype 1 Slow Responders
Peginterferon Alfa-2b and Weight-Based Dosing of Ribavirin Treatment Effective and Safe in Obese HCV-Infected Patients
Weight-Based Peginterferon Alfa-2b and Ribavirin Associated With Early Virologic Response in Most HCV Genotype 1 Patients
Response Rates to Peginterferon alfa-2b and Ribavirin Lower in Hispanic Patients
Cumulative Exposure to Peginterferon Alfa-2a and Ribavirin Predictive of SVR in Patients With HCV Genotype 2 or 3
Telaprevir-Resistant HCV Variants Remain Susceptible to Standard Peginterferon/Ribavirin Therapy
Genetic Cirrhosis Risk Score More Accurate Than Clinical Factors for Detection of Risk of Cirrhosis in Chronic Hepatitis C Patients
Monotherapy With HCV Polymerase Inhibitor R1626 Results in Robust Decreases in Genotype 1 HCV RNA in a Dose-Dependent Manner
High-Dose Taribavirin (Viramidine) Sustains Virologic Response for Hepatitis C Virus–Infected Patients With Minimal Impact on Anemia
Eltrombopag Allows Significantly More Hepatitis C Patients With Thrombocytopenia to Initiate Peginterferon/Ribavirin Therapy
Consensus Interferon Plus Ribavarin Results in End of Treatment Response in up to 25% of Previous Peginterferon Nonresponders
Equal SVR Rates in Rapid Virologic Responders Treated With Peginterferon Alfa-2b Plus Taribavirin (Viramidine) or Ribavirin

Expert Analysis

Advances in HCV Treatment: 2006

Faculty:
Nezam H. Afdhal, MD, FRCPI Karen L. Lindsay, MD, MMM Mitchell L. Shiffman, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the results of recent studies of diagnostic tests for viral hepatitis and its complications
Discuss the latest treatments, both approved and experimental, for acute and chronic hepatitis and its complications
Review the epidemiology, pathogenesis, and natural history of acute and chronic hepatitis

CME CREDIT INFORMATION

Release Date: 12/13/06

Expiration Date: 12/12/07

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.6 contact hours (0.16 CEUs)

Registered Nurses: 2 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.